Abstract
Modern treatment of childhood acute leukemias started with the use of methotrexate (MTX) by Farber and colleagues in 1948 (reviewed in Dawn of Chemotherapy of Childhood Cancer) (Wolff 1999). The first observations of risk categorizations came in 1949 when Wolf Zuelzer noted that in patients treated with supportive care alone, those with initial white blood cell (WBC) counts of less than 10,000/μL survived longer than those with higher WBC counts (Zuelzer 1949). Subsequently, Dr. Roger Hardisty called attention to a lymphosarcoma variant that is detectable on chest X-ray by the presence of mediastinal enlargement. In 1975, two groups of investigators (from St. Jude Children’s Hospital, Memphis and Children’s Hospital of Michigan, Detroit) simultaneously showed that the so-called lymphosarcoma variant is of T-cell lineage (Ravindranath et al. 1975; Sen and Borella 1975), and in 1978 Secker-Walker, Lawler, and Hardisty (Secker-Walker et al. 1978) showed the critical importance of cytogenetics in childhood common acute lymphoblastic leukemia (ALL). Shortly thereafter, immunophenotyping and cytogenetic evaluation of childhood ALL became a standard practice.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Similar content being viewed by others
References
Agarwal BMR, Kurkure P, Choudhry V, Dalvi R, Johnsolomon P et al (2001) Indian National Training Project in Practical Pediatric Oncology (INTPPPO): evaluation of progress and lessons for the future. Med Pediatr Oncol 37(3):163
Baez F, Ocampo E et al (1997) Treatment of childhood Hodgkin’s disease with COPP or COPP-ABV (hybrid) without radiotherapy in Nicaragua. Ann Oncol 8(3):247–250
Barr RD, Ribeiro RC, Agarwal BR et al (2006) Pediatric oncology in countries with limited resources. Lippincott Williams and Wilkins, Philadelphia
D’Angio GJ (2009) The La Mascota project. J Pediatr Hematol Oncol 31(10):709
Day SW, Dycus PM et al (2008) Quality assessment of pediatric oncology nursing care in a Central American country: findings, recommendations, and preliminary outcomes. Pediatr Nurs 34(5):367–373
Edefonti A, Montini G, Castellon M (for the Nicaraguan Network of Pediatric Nephrology – NINEPEN) (2010) comprehensive cooperative project for children with renal disease in Nicaragua. Clin Nephrol (in press)
Giovannetti E, Ugrasena DG et al (2008) Methylenetetrahydrofolate reductase (MTHFR) C677T and thymidylate synthase promoter (TSER) polymorphisms in Indonesian children with and without leukemia. Leuk Res 32(1):19–24
Harif M, Barsaoui S et al (2008) Treatment of B-cell lymphoma with LMB modified protocols in Africa–report of the French-African Pediatric Oncology Group (GFAOP). Pediatr Blood Cancer 50(6):1138–1142
Hesseling PB (2000) The SIOP burkitt lymphoma pilot study in Malawi, Africa. Med Pediatr Oncol 34(2):142
Hesseling PB, Molyneux E et al (2008) Treating Burkitt’s lymphoma in Malawi, Cameroon, and Ghana. Lancet Oncol 9(6):512–513
Howard SC, Pedrosa M et al (2004) Establishment of a pediatric oncology program and outcomes of childhood acute lymphoblastic leukemia in a resource-poor area. JAMA 291(20): 2471–2475
Howard SC, Ortiz R et al (2007) Protocol-based treatment for children with cancer in low income countries in Latin America: a report on the recent meetings of the Monza International School of Pediatric Hematology/Oncology (MISPHO) – part I. Pediatr Blood Cancer 48(4): 486–490
Hunger SP, Winick NJ et al (2005) Therapy of low-risk subsets of childhood acute lymphoblastic leukemia: when do we say enough? Pediatr Blood Cancer 45(7):876–880
Hunger SP, Sung L et al (2009) Treatment strategies and regimens of graduated intensity for childhood acute lymphoblastic leukemia in low-income countries: a proposal. Pediatr Blood Cancer 52(5):559–565
Jemal A, Siegel R et al (2007) Cancer statistics, 2007. CA Cancer J Clin 57(1):43–66
Kazembe P, Hesseling PB et al (2003) Long term survival of children with Burkitt lymphoma in Malawi after cyclophosphamide monotherapy. Med Pediatr Oncol 40(1): 23–25
Masera G (2009) Bridging the childhood cancer mortality gap between economically developed and low-income countries. J Pediatr Hematol Oncol 31(10):710–712
Masera G, Baez F et al (1998) North-South twinning in paediatric haemato-oncology: the La Mascota programme, Nicaragua. Lancet 352(9144):1923–1926
Masera G, Baez F, Biondi A et al (2004) Bridging the childhood cancer mortality gap between economically developed and low income countries: lessons from the MISPHO experience. In: Tannenberg S, Cavalli F, Pannuti F (eds) Cancer in developing countries. The great challenge for oncology in the 21st century. Verlag, Muenchen-Bern-Wien-New York, Zuckschwerdt, pp 42–60
Mitchell CD, Richards SM et al (2005) Benefit of dexamethasone compared with prednisolone for childhood acute lymphoblastic leukaemia: results of the UK Medical Research Council ALL97 randomized trial. Br J Haematol 129(6): 734–745
Mostert S, Sitaresmi MN et al (2006) Influence of socioeconomic status on childhood acute lymphoblastic leukemia treatment in Indonesia. Pediatrics 118(6):e1600–1606
Mostert S, Sitaresmi MN et al (2008) Parental experiences of childhood leukemia treatment in indonesia. J Pediatr Hematol Oncol 30(10):738–743
Ravindranath Y, Kaplan J et al (1975) Significance of mediastinal mass in acute lymphoblastic leukemia. Pediatrics 55(6): 889–893
Ribeiro RC, Pui CH (2005) Saving the children – improving childhood cancer treatment in developing countries. N Engl J Med 352(21):2158–2160
Ribeiro RC, Rego E (2006) Management of APL in developing countries: epidemiology, challenges and opportunities for international collaboration. Hematol Am Soc Hematol Educ Program 1:162–168
Ribeiro RC, Steliarova-Foucher E et al (2008) Baseline status of paediatric oncology care in ten low-income or mid-income countries receiving My Child Matters support: a descriptive study. Lancet Oncol 9(8):721–729
Rohatiner A (2005) Keynote comment: not just an exercise in solidarity. Lancet Oncol 6(11):818–819
Secker-Walker LM, Lawler SD et al (1978) Prognostic implications of chromosomal findings in acute lymphoblastic leukaemia at diagnosis. Br Med J 2(6151):1529–1530
Sen L, Borella L (1975) Clinical importance of lymphoblasts with T markers in childhood acute leukemia. N Engl J Med 292(16):828–832
Simone J, Aur RJ et al (1972) “Total therapy” studies of acute lymphocytic leukemia in children. Current results and prospects for cure. Cancer 30(6):1488–1494
Sitaresmi MN, Mostert S et al (2009) Chemotherapy-related side effects in childhood acute lymphoblastic leukemia in Indonesia: parental perceptions. J Pediatr Oncol Nurs 26(4): 198–207
Slats AM, Egeler RM et al (2005) Causes of death – other than progressive leukemia – in childhood acute lymphoblastic (ALL) and myeloid leukemia (AML): the Dutch Childhood Oncology Group experience. Leukemia 19(4):537–544
Te Poele EM, de Bont ES et al (2007) Dexamethasone in the maintenance phase of acute lymphoblastic leukaemia treatment: is the risk of lethal infections too high? Eur J Cancer 43(17):2532–2536
The Montevideo Document (1997) SIOP News 17:32
Veerman AJ, Sutaryo S et al (2005) Twinning: a rewarding scenario for development of oncology services in transitional countries. Pediatr Blood Cancer 45(2):103–106
Veerman AJ, Kamps WA et al (2009) Dexamethasone-based therapy for childhood acute lymphoblastic leukaemia: results of the prospective Dutch Childhood Oncology Group (DCOG) protocol ALL-9 (1997-2004). Lancet Oncol 10(10): 957–966
Wagner H (2001) Alliances in pediatric oncology: where do we go from here? Med Pediatr Oncol 36(2):310–311
Wagner HP, Antic V (1997) The problem of pediatric malignancies in the developing world. Ann N Y Acad Sci 824: 193–204
Werner D, Bower B (1982) Helping health workers learn. Hesperian Foundation, Palo alto, CA
Widjajanto PH, Veerman AJP, Sutaryo (2006) apoptotic cell identification: An in vivo study during induction treatment of childhood acute lymphoblastic leukemia. Paediatrica Indonesiana 46:195–198
Wolff JA (1999) Chronicle: first light on the horizon: the dawn of chemotherapy. Med Pediatr Oncol 33(4):405–407
Zeulzer WW, Ravindranath Y et al (1976) IMFRA (intermittent intrathecal methotrexate and fractional radiation) plus chemotherapy in childhood leukemia. Am J Hematol 1(2): 191–199
Zuelzer WW (1949) Current trends in hematology. Pediatrics 4(3):269–276
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2011 Springer Berlin Heidelberg
About this chapter
Cite this chapter
Ravindranath, Y. et al. (2011). Improved Outcome for Children with Acute Leukemia: How to Address Global Disparities. In: Reaman, G., Smith, F. (eds) Childhood Leukemia. Pediatric Oncology. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-642-13781-5_12
Download citation
DOI: https://doi.org/10.1007/978-3-642-13781-5_12
Published:
Publisher Name: Springer, Berlin, Heidelberg
Print ISBN: 978-3-642-13780-8
Online ISBN: 978-3-642-13781-5
eBook Packages: MedicineMedicine (R0)